Track all markets on TradingView
Blood Cancer-Focused Blueprint Medicines Could Be ‘Attractive Target For Partnerships’: Analyst
Media

Blood Cancer-Focused Blueprint Medicines Could Be ‘Attractive Target For Partnerships’: Analyst

  • November 15, 2024
  • 1 View

JP Morgan initiates coverage on Blueprint Medicines, highlighting Ayvakit’s significant growth, 2024 revenue forecast, and potential strategic opportunities.

Latest Ratings for BPMC

Date Firm Action From To
Mar 2022 Stifel Maintains Buy
Mar 2022 Citigroup Initiates Coverage On Neutral
Feb 2022 SVB Leerink Downgrades Outperform Market Perform

View More Analyst Ratings for BPMC

View the Latest Analyst Ratings

read more

​ 

​JP Morgan initiates coverage on Blueprint Medicines, highlighting Ayvakit’s significant growth, 2024 revenue forecast, and potential strategic opportunities.

Latest Ratings for BPMC
DateFirmActionFromTo Mar 2022StifelMaintainsBuy Mar 2022CitigroupInitiates Coverage OnNeutral Feb 2022SVB LeerinkDowngradesOutperformMarket Perform
View More Analyst Ratings for BPMC

View the Latest Analyst Ratings

read more 

Share This Post:

Leave a Reply

Your email address will not be published. Required fields are marked *

This material is for informational purposes is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of date of publication and are subject to change. Reliance upon information in this material is at the sole discretion of the reader. Past performance is not indicative of current or future results. This information provided is neither tax nor legal advice and investors should consult with their own advisors before making investment decisions. Investment involves risk including possible loss of principal.